Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives

Cancer statistics, 2023

(2023) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Safety of MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review

(2022) Alexis Cortot et al.   Clinical Lung Cancer

Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer

(2022) Ying Fan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cancer treatment and survivorship statistics, 2022

(2022) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.

(2022) Yi-Long Wu et al.   JOURNAL OF CLINICAL ONCOLOGY

Annual report to the nation on the status of cancer, part 1: National cancer statistics

(2022) Kathleen A. Cronin et al.   CANCER

Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report

(2022) Liang-Wei Tseng et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MET alterations in non-small cell lung cancer – current perspectives and future challenges

(2022) Jordi Remon et al.   Journal of Thoracic Oncology

Oncogene alterations in non-small cell lung cancer—have we MET a new target?

(2022) Wolfram C. M. Dempke et al.   Translational Lung Cancer Research

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study

(2022) Jürgen Wolf et al.   EUROPEAN JOURNAL OF CANCER

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts

(2021) Kaibin Zhu et al.   Aging-US

1256P Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial

(2021) R.S. Heist et al.   ANNALS OF ONCOLOGY

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

(2021) Keunchil Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

(2021) Juergen Wolf et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

(2021) Leylah M. Drusbosky et al.   Journal of Hematology & Oncology

MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING

(2021) Yong Zhang et al.   Cancer Discovery

Roles of MET in human cancer

(2021) Xin Yang et al.   CLINICA CHIMICA ACTA

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

(2020) Paul K. Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

(2020) Jürgen Wolf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I dose‐escalation study of capmatinib ( INC 280) in Japanese patients with advanced solid tumors

(2019) Taito Esaki et al.   CANCER SCIENCE

Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway

(2019) Yuyao Shen et al.   MOLECULAR AND CELLULAR PROBES

Capmatinib for the treatment of non-small cell lung cancer

(2019) Johan Filip Vansteenkiste et al.   Expert Review of Anticancer Therapy

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC

(2017) William Sterlacci et al.   VIRCHOWS ARCHIV

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

(2016) J. H. Tong et al.   CLINICAL CANCER RESEARCH

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

(2008) Katsuhiro Okuda et al.   CANCER SCIENCE